View Older Stories View More Recent Stories

Mar 31, 2023 08:15AM Ocugen Chief Scientific Officer to Present at 2023 World Vaccine Congress
Mar 27, 2023 08:00AM Ocugen (OCGN) Announces FDA Approval for Enrollment of Pediatric Patients in Ongoing OCU400 Phase 1/2 Clinical Trial
Mar 27, 2023 08:00AM Ocugen Announces FDA Approval for Enrollment of Pediatric Patients in Ongoing OCU400 Phase 1/2 Clinical Trial for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)
Mar 27, 2023 08:00AM Ocugen Announces FDA Approval for Enrollment of Pediatric Patients in Ongoing OCU400 Phase 1/2 Clinical Trial for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)
Mar 7, 2023 08:00AM Ocugen, Inc. to Participate in Fireside Chat at 35th Annual Roth Conference
Mar 7, 2023 08:00AM Ocugen, Inc. to Participate in Fireside Chat at 35th Annual Roth Conference
Mar 6, 2023 07:06AM Ocugen (OCGN) Appoints Quan A. Vu as CFO
Mar 6, 2023 07:02AM Ocugen Appoints Quan A. Vu to Chief Financial Officer & Chief Business Officer
Mar 6, 2023 07:02AM Ocugen Appoints Quan A. Vu to Chief Financial Officer & Chief Business Officer
Feb 28, 2023 05:55AM Ocugen (OCGN) Submits iNDA to Initiate a Phase 1 Trial of OCU200
Feb 27, 2023 05:57PM Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 1 Clinical Trial Evaluating OCU200 for the Treatment of Diabetic Macular Edema
Feb 27, 2023 05:57PM Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 1 Clinical Trial Evaluating OCU200 for the Treatment of Diabetic Macular Edema
Feb 17, 2023 08:00AM Ocugen to Present at Retinal Vascular Disease Drug Development Summit
Feb 17, 2023 08:00AM Ocugen to Present at Retinal Vascular Disease Drug Development Summit
Feb 15, 2023 04:30PM Ocugen to Host Conference Call on Tuesday, February 28 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2022 Financial Results
Feb 15, 2023 04:30PM Ocugen to Host Conference Call on Tuesday, February 28 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2022 Financial Results
Feb 1, 2023 08:05AM Ocugen (OCGN) Appoints Quan A. Vu as Chief Business Officer
Feb 1, 2023 08:00AM Ocugen Appoints Quan A. Vu as Chief Business Officer
Feb 1, 2023 08:00AM Ocugen Appoints Quan A. Vu as Chief Business Officer
Jan 31, 2023 08:00AM Ocugen, Inc. to Present at 2023 BIO CEO & Investor Conference
Jan 31, 2023 08:00AM Ocugen, Inc. to Present at 2023 BIO CEO & Investor Conference
Jan 9, 2023 06:00AM Ocugen (OCGN) Reports Positive Phase 2/3 Top-Line Data for COVAXIN
Jan 9, 2023 06:00AM Ocugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN™ (BBV152) in Phase 2/3 Immuno-bridging and Broadening Study: Both Co-primary Endpoints Met
Jan 9, 2023 06:00AM Ocugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN™ (BBV152) in Phase 2/3 Immuno-bridging and Broadening Study: Both Co-primary Endpoints Met
Dec 16, 2022 06:31AM Ocugen (OCGN) Announces Phase 3 Confirmatory Clinical Trial Agreement for NeoCart
Dec 16, 2022 06:30AM Ocugen Announces Phase 3 Confirmatory Clinical Trial Agreement for NeoCart®
Dec 16, 2022 06:30AM Ocugen Announces Phase 3 Confirmatory Clinical Trial Agreement for NeoCart®
Dec 15, 2022 05:15PM Ocugen Announces OCU400 Receives Orphan Drug Designations for Retinitis Pigmentosa and Leber Congenital Amaurosis
Dec 13, 2022 08:00AM Ocugen, Inc. to Ring the Nasdaq Stock Market Closing Bell
Dec 13, 2022 08:00AM Ocugen, Inc. to Ring the Nasdaq Stock Market Closing Bell
Dec 7, 2022 08:12AM Ocugen (OCGN) Announces Update on OCU400 Phase 1/2 Clinical Trial Targeting Retinitis Pigmentosa and Leber Congenital Amaurosis
Dec 7, 2022 08:00AM Ocugen Announces Update on OCU400 Phase 1/2 Clinical Trial Targeting Retinitis Pigmentosa and Leber Congenital Amaurosis
Dec 7, 2022 08:00AM Ocugen Announces Update on OCU400 Phase 1/2 Clinical Trial Targeting Retinitis Pigmentosa and Leber Congenital Amaurosis
Nov 28, 2022 07:30AM Ocugen to Present at 3rd Annual Dry AMD Therapeutics Summit
Nov 28, 2022 07:30AM Ocugen to Present at 3rd Annual Dry AMD Therapeutics Summit
Nov 8, 2022 07:30AM Ocugen Provides Business Update & Third Quarter 2022 Financial Results
Nov 8, 2022 07:30AM Ocugen Provides Business Update & Third Quarter 2022 Financial Results
Oct 27, 2022 07:30AM Ocugen to Host Conference Call on Tuesday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2022 Financial Results
Oct 27, 2022 07:30AM Ocugen to Host Conference Call on Tuesday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2022 Financial Results
Oct 19, 2022 07:30AM Ocugen to Host R&D Day in New York City on Tuesday, November 1, 2022
Oct 19, 2022 07:30AM Ocugen to Host R&D Day in New York City on Tuesday, November 1, 2022
Oct 13, 2022 04:33AM Ocugen (OCGN) Completes Dosing in OCU400 Phase 1/2 Cohort 2
Oct 12, 2022 05:37PM Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2
Oct 12, 2022 05:37PM Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2
Oct 6, 2022 08:00AM Ocugen, Inc. to Present at Upcoming Vaccines, Cell & Gene Therapy Conferences
Oct 6, 2022 08:00AM Ocugen, Inc. to Present at Upcoming Vaccines, Cell & Gene Therapy Conferences
Sep 29, 2022 07:30AM Ocugen, Inc. to Present at Chardan’s 6th Annual Genetic Medicines Conference
Sep 29, 2022 07:30AM Ocugen, Inc. to Present at Chardan’s 6th Annual Genetic Medicines Conference
Sep 28, 2022 06:31AM Ocugen (OCGN) Enters Agreement With Washington University in St. Louis for Commercialization of Intranasal COVID-19 Vaccine in US, Europe and Japan
Sep 28, 2022 06:30AM Ocugen Announces Agreement With Washington University in St. Louis for Commercialization of Intranasal COVID-19 Vaccine in U.S., Europe, and Japan
View More Recent Stories View Older Stories